Rene Bernards - Director at Lixte Biotechnology Holdings, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Options to Purchase Common Stock	4.17K			Jan 20, 2025	Direct	Common
Options to Purchase Common Stock	4.15K			Jun 30, 2024	Direct	Common

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.